

“KNOWING WHAT IS FEASIBLE” IN CLINICAL TRIALS

MAEVE KELSEY
CLINICAL TRIALS NURSE MANAGER
CRF - C

CHALLENGE

Many clinical studies fail to recruit sufficient numbers of participants

- Wastes valuable resources and time
- Potentially delays treatments becoming available to patients.
- Incomplete recruitment to studies leads to significant opportunity costs.



Stock photo – Image ID: 1006556.jpg

<http://freedigitalphotos.net>

WHAT IS FEASIBILITY?

- Conducting clinical trial feasibility is one of the first steps in clinical trial conduct.
- A robust feasibility ensures a realistic assessment of capability to conduct the clinical trial.
- Overall objective is delivering a project to completion:
 - On time
 - To target
 - And within budget

KEY QUESTIONS


- **Not just about numbers!**
- Relevance and intensity of the study for participants and the study team.
- We need to think about whether the study is:
 - Compatible with current practice?
 - Consistency in practice e.g. is the control treatment schedule appropriate?
 - Inclusion/exclusion criteria restrictions

CLINICAL RELEVANCE – PATIENT PERSPECTIVE

- Consider the patient's perspective
- Suggest – consult with patient support groups/charities at the beginning
- **Patient and Public Involvement (PPI)** can improve trial feasibility and recruitment by addressing questions such as:
 - Will the recruitment plan work?
 - Can we make it **easier** to **encourage** patients to participate?
 - Are patients going to **accept** the **study schedule** and requirements?
 - How could it be made easier to **retain** the patient?



RECRUITMENT CAN BE FRUSTRATING!



Stock photo – Image ID: 10094885.jpg
<http://freedigitalphotos.net>

Trends in Clinical Trial Site Selection & Patient Recruitment

THE CHANGING LANDSCAPE »

80% of trials fail to meet enrollment timelines¹

Up to 50% of research trial sites enroll one or no patients²

Competition for trial sites, investigators and patients continues to rise.

of trials registered at clinicaltrials.gov tripled 2000-2014

Why?

- Increasingly complex trial protocols
- Competition for patients in certain therapeutic areas
- Expanded global landscape
- Increased regulatory requirements

INVESTIGATOR/SITE SELECTION

- **The sponsor is responsible** for selecting the investigators and sites.
- Careful selection and evaluation of investigator sites is critical:
 - for the successful completion of a trial within budget
 - timelines
 - to ensure high quality data
- How will Investigator site be selected?
- Previous experience working with the sponsor

INVESTIGATOR/SITE SELECTION – EVIDENCE

- Interest in the research question.
- Availability of suitable patient population
- Audit figures
- Conflicting studies

SPONSOR CONSIDERATIONS

- **Site demographics**
 - Clinical trial experience
 - Availability of study coordinators, research nurses, pharmacists
 - Experience conducting studies involving EDC and interactive Web response system (IWRS)
- **Quality management**
 - Standard operating procedures
 - Experience and results of audits and inspections. Were any concerns raised.
- **Local processes**
 - approvals, agreements etc
 - Ethics committee requirements

INVESTIGATOR SITE SELECTION - RESOURCES

- **Adequate facilities:**
 - Availability of any specialised diagnostic or therapeutic equipment
 - Adequate space and storage conditions (including archive)
 - Equipment
 - e.g. fridges, freezers, non standard equipment?
 - Pharmacy support - Drug storage, etc
 - Laboratory support - processing of biological samples
 - Radiology support

INVESTIGATOR RESPONSIBILITIES - RESEARCH STAFF

- The Investigator should have sufficient time to properly conduct and complete the trial **(ICH GCP 4.2.2)**
 - i.e. Be available for patient assessment , consenting, etc.
- The investigator should have available an adequate number of qualified staff and adequate facilities **(ICH GCP 4.2.3)**
- The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the IP and their trial-related duties and functions **(ICH GCP 4.2.4)**

➤ **Investigator – not sponsor – responsibility!**

HOW IS FEASIBILITY ASSESSED?

- Initial contact - Protocol summary provided for review
- Site Assessment Form completed by PI
- Confidentiality agreement signed → Full protocol or synopsis of protocol provided
- **Site assessment visit**
 - Sponsor makes decision about site selection
 - Investigator makes decision about whether to proceed

SITE ASSESSMENT VISIT

- Attended by Sponsor or CRO representative/s, Investigator, Study Coordinator/Research Nurse/ Ancillary staff
 - Discussion of logistics of trial
 - Tour of facilities
 - Opportunity to identify local issues/requirements e.g. Processes to gain necessary approvals at site
 - Opportunity to discuss budget issues e.g. set-up costs, archiving costs

ITEMS THAT MAY BE UNDERESTIMATED WHEN CONSIDERING A STUDY!

- Unscheduled patient visits or follow-up activities
- Time spent with CRA/auditors, resolving queries, following up AEs etc
- Payment for recruitment activities, screen failures, patients that withdraw from study
- Patient expenses – e.g. parking, transport, meals
- Training Costs
- Archiving costs

CONCLUSION

- Feasibility assessment is **an investment** to ensure a good study outcome for all parties - sponsor - investigators - patients
- Unmet recruitment targets are costly for both the sponsor and the investigator/site
- Unrealistic projections can impact on a sites selection for future studies

Thank you